280. Huge arteriovenous malformation with cervicofacial or limb lesion Clinical trials / Disease details
Clinical trials : 25 / Drugs : 29 - (DrugBank : 15) / Drug target genes : 14 - Drug target pathways : 153
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-003573-26-BE (EUCTR) | 18/12/2019 | Evaluating the safety and efficacy of Trametinib in Arterio-Venous Malformations that are refractory to standard care | Monocentric pilot trial evaluating efficacy of Trametinib in Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated - TRAMAV | Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Mekinist Product Name: Mekinist | Cliniques universitaires Saint-Luc | NULL | NA | Female: yes Male: yes | 20 | Phase 2 | Belgium |